Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Paul K. Paik, Linda Su Hyun Ahn, Michelle S. Ginsberg, Andrew J. Plodkowski, Rachel Kim, L. Austin Doyle, Charles M. Rudin | ||||||||||||
Title | Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228. | ||||||||||||
|
|||||||||||||
URL | http://abstracts.asco.org/239/AbstView_239_265315.html | ||||||||||||
Abstract Text | J Clin Oncol 37, 2019 (suppl; abstr 9085) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KEAP1 mutant | lung squamous cell carcinoma | predicted - sensitive | Sapanisertib | Case Reports/Case Series | Actionable | In a Phase II trial, Sapanisertib (MLN0128) treatment resulted in a disease control rate of 66% (2/3, 2 stable disease) in lung squamous cell carcinoma patients harboring KEAP1 mutations (J Clin Oncol 37, 2019 (suppl; abstr 9085)). | detail... |